[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Molecular Diagnostics Market Report: 2011 Edition

June 2011 | 43 pages | ID: M1E934F1745EN
Koncept Analytics

US$ 800.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Molecular diagnostics refers to the technique of identifying the presence of any infection or disease, gene mutations, or any type of antigens attacking the body, with the help of the genetic and protein activity patterns of the body. Primarily, the molecular diagnostic tests are performed for three purposes: diagnosis of the infectious diseases, genetic identification and the diagnosis of genetic diseases. Currently, molecular diagnostics represent a small share in the in-vitro diagnostics market, but it offers immense opportunities for growth in future and therefore, is likely to drive the in-vitro diagnostics market in the foreseeable future.

Diagnostic tests play an important role in helping the physicians in making decisions, as it has been found that around 80% of the physicians’ decisions are based on the diagnostic reports. With the advent of faster and more accurate molecular tests, coupled with the better sensitivity and specificity of the molecular tests, there has been a shift from the traditional testing methods towards the molecular diagnostic tests.

Presently, the molecular diagnostic market is growing on the back of oncology and the infectious disease segment, but in future, when these segments are likely to approach saturation, some of the other segments, including CT/GC, HPV, HAI and Influenza are expected to offer opportunities for growth. The US, Europe and Japan are the major markets for molecular diagnostic tests and together account for a lion’s share in the global market. But in the coming years, with the increasing per capita income, and rising concern regarding healthy living in the emerging countries, like India and China, such countries offer immense potential for growth.

Continuous innovation and the technological advancements are some of the factors responsible for accelerating the growth of molecular diagnostic market. However, some of the other major factors affecting the industry include the increasing incidences of cancer, the rising number of cases of hepatitis B and tuberculosis and the availability of various molecular diagnostic tests.

The molecular diagnostics market is quite consolidated with the top seven players holding major share of the market, including Roche, Novartis, Gen Probe, QIAGEN, Bayer, Abbott, and Becton Dickinson.

The current report analyzes the molecular diagnostic market on the global basis. It also presents a view of the various segments of the market. The report discusses the drivers and challenges prevailing in the molecular diagnostics industry. It presents the competitive conditions prevailing in the global molecular diagnostic market, along with the profiles of four major players in the industry, Roche, Gen-Probe, QIAGEN, and Bayer.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the industry. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
1. INTRODUCTION

1.1 In Vitro Diagnostics: Industry Overview
1.2 Molecular diagnostics

2. GLOBAL IN-VITRO DIAGNOSTICS MARKET

Market Value & Growth Rate
Key Segments

3. GLOBAL MOLECULAR DIAGNOSTICS MARKET

3.1 Market Size
  Market Share by Segments
  Market Share by Applications
3.2 Market Segments
  3.2.1 Cancer
  3.2.2 HPV (Human Papillomavirus)
  3.2.3 Theranostics

4. MARKET DYNAMICS

4.1 Opportunities for Growth
  4.1.1 CT/GC Market
  4.1.2 HPV Tests
  4.1.3 Hospital Acquired Infections (HAI)
  4.1.4 Influenza Molecular Tests
  4.1.5 Growth of Companion Diagnostic Tests
  4.1.6 Growth in the Emerging Markets
4.2 Growth Drivers
  4.2.1 Rapidly ageing Population
  4.2.2 Shift towards Molecular Diagnostics
  4.2.3 Rising Health Care Costs
  4.2.4 High returns on investment (ROI)

5. KEY ISSUES

5.1 Lack of Skilled Workforce
5.2 Complex Reimbursement Conditions

6. COMPETITIVE LANDSCAPE

Competitive Overview
Market Share
Financial Comparison

7. COMPANY PROFILES

7.1 Roche Holdings AG
  Company Overview
  Key Financials
  Business Strategies
  Innovation to Tap Potential of Modern Science
  Providing Personalized Healthcare
  Focus on Unmet Medical Needs
  Increase in Research and Development
7.2 Gen-Probe
  Company Overview
  Key Financials
  Business Strategies
  Expansion through Acquisitions
  Increasing Commitment to Quality
  Focus on Innovation
  Marketing Strategy
7.3 QIAGEN
  Company Overview
  Key Financials
  Business Strategies
  Wide Geographical Presence
  Focus on Strategic Objectives
  Increasing Investment in Research and Development
7.4 Bayer AG
  Company Overview
  Key Financials
  Business Strategies
  Obtaining Leadership in all Segments
  Health Care Strategy

8. MARKET OUTLOOK

8.1 Market Forecast
8.2 Forecast Methodology
  8.2.1 Dependent and Independent Variables
  8.2.2 Correlation Analysis
  8.2.3 Regression Analysis

LIST OF CHARTS

IVD Market – Segments by Technology
Molecular Diagnostcs – Traditional Process
Main Purposes of Molecular Diagnostics
Global IVD Market Size (2002-2009)
Global IVD Market-by Clinical Segments (2009)
Global IVD Market-Share by Segments (2014)
Global Molecular Diagnostics Equipment Market (2003-2010E)
Global Molecular Diagnostics Market-Share by Segments (2008)
Global Molecular Diagnostics Market-Share by Application Areas (2010)
Global Molecular Diagnostic Testing Market for Cancer (2001-2012)
Global HPV Market-Value Share by Region (2009)
Chinese HPV Market-Share by Companies (2009)
Global Molecular Diagnostic Testing Market for Theranostics (2002-2012)
CT/GC Revenue Share-by Major Companies (2007-2009)
Ageing Population Worldwide (age>65) 2005-2015
Cancer Costs-by Type (2010 & 2020)
Worldwide Molecular Diagnostic Market-Share by Companies (2010)
DNA Based Diagnostic Test Equipment Market-Share by Companies (2009)
Roche Revenue (2006-2010)
Roche Revenue-Share by Segments (2010)
Roche/Genetech-Share of Projects in Research & Early Phase (Jan 2011)
Roche and Genetech-Share of Projects in Phase III (Jan ‘11)
Gen-Probe Revenue (2006-2010)
Gen-Probe Revenue-by Sources (2010)
QIAGEN Revenue (2006-2010)
QIAGEN Revenue-Share by Source of Revenue (2010)
QIAGEN Revenue-Share by Geographic Segments (2010)
Bayer AG Revenue (2006-2010)
Bayer AG Revenue-Share by Segments (2010)
Global Molecular Diagnostics Market Forecast (2010 – 2014E)
List of Tables
Top 10 Global IVD Market (2008 and 2015)
National Limitation Amount for CPT Codes (2009-2010)
US Molecular Testing Platforms-by Major Companies
Financial Position of Key Players (2010)
Dependent & Independent Variables (2003 – 2010)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output


More Publications